

24 February 2015

ANTEO TECHNOLOGIES FILES NEW PATENT New Bioseparations Patent For Sample Pre-Treatment

Anteo Diagnostics Limited, ASX: ADO advises that a new patent application, which provides a method to remove or decrease interference in a sample, was filed on Friday 20 February 2015 by its subsidiary Anteo Technologies Pty Ltd.

In late 2013, Anteo Diagnostics Limited raised funds to accelerate work in the field of bioseparations. Several patent filings have been announced since then and this filing is a valuable addition to that estate.

Dr Geoff Cumming, CEO, said: "This is a positive step forward as we continue to build our suite of patents using our technology platform, Mix&Go™. Our latest application builds on previously filed patents and strengthens our IP position."

"It is most encouraging that a number of the companies behind our existing collaborations, such as the PoC1 project, have already expressed an interest in this invention. Use of the IP covered by this patent on the PoC1 sensor surface could further improve outcomes with the device," said Dr Cumming.

Background

Laboratory testing plays a critical role in health assessment, health care, and ultimately, the public's health. Test results contribute to diagnosis of disease, monitoring of treatment and health status, and population screening for disease. Laboratory testing affects people in every life stage, and almost everyone will have one or more laboratory tests conducted during their lifetime.

The Market

An estimated 7 to 10 billion laboratory tests are performed each year in the United States alone. Laboratory test results influence approximately 70% of medical decisionsⁱ. The global immunoassay market is substantial and considerable growth is forecastⁱⁱ.

The expanding use of immunoassays, new and innovative product launches by key industry players, increasing demand for high quality healthcare services and the rapidly increasing geriatric population are the major factors driving the global market. Tremendous growth is expected in the next five years, as this market includes the high throughput automated systems that offer the highest sensitivity.

The drive to near patient testing has led to accelerating usage of immunoassay-based point-of-care (PoC) tests to diagnose various diseases in such diverse

fields as oncology, cardiology and diabetes, and conditions such as pregnancy.

About the Patent

This invention covers approaches for clearing or depleting interfering substances from pathology samples prior to testing.

Simply, a specimen that requires testing is prone to pollution or 'interference', which is the effect of a substance present in the sample that alters the correct value of the result, (Kroll & Elin, 1994).

There is a need for a simple, cheap, and effective solution to pre-treat samples, such as human serum and plasma specimens in the laboratory to mitigate this risk.

Summary of the Disclosure

Anteo Technologies' patent provides a method to remove or decrease interference in a sample without damaging the integrity of that sample. Further, the method removes the need for expensive and time-consuming additional steps.

This invention can incorporate the products that Anteo Technologies already commercialises. As is the case with Anteo's complete platform, this invention creates the surface scientists want on the surface they have.

****Ends****

Anteo Technologies

www.anteotech.com

Anteo Technologies Pty Ltd

Anteo uses its patented technology to develop, manufacture and commercialise proprietary surface coatings for use in healthcare, life sciences and beyond. Its patented technology is applied in the Mix&Go product range, which delivers solutions to the challenges of establishing highly functional biological interfaces between fragile biomolecules, and synthetic, and often incompatible, materials.

Bio-Layer Pty Ltd, a subsidiary company of Anteo Diagnostics Limited (ASX: ADO) has recently changed its name to Anteo Technologies Pty Ltd. This change does not affect Anteo Diagnostics' shareholders.

ⁱ <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5413a1.htm>

ⁱⁱ <http://www.marketsandmarkets.com/Market-Reports/immunoassay-market-436.html>